Avalyn Pharma Inc. (AVLN) Revenue, Earnings & Financial Statements
$27.92NASDAQ: AVLNMarket Cap $1.24B
Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)
Avalyn Pharma Inc. most recently reported annual revenue of $0, a net loss of $85.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Income Statement — 1 Years (USD millions)
Metric
2025
Revenue
$0
Operating Expenses
$91.0M
Operating Profit
−$91.0M
Other Income
$6.0M
Interest
$0
Depreciation
$0
Profit Before Tax
−$85.0M
Tax rate (%)
0.0%
Net Profit
−$85.0M
EPS
−$2.04
Quarterly Results — Last 5 Quarters (USD millions)
Metric
Mar '25
Jun '25
Mar '26
Jun '26
Sep '26
Revenue
$0
$0
$0
$0
$0
Operating Expenses
$19.0M
$22.0M
$28.0M
$31.0M
$33.0M
Operating Profit
−$19.0M
−$22.0M
−$28.0M
−$31.0M
−$33.0M
Interest
$0
$0
$0
$0
$0
Profit Before Tax
−$18.0M
−$20.0M
−$27.0M
−$29.0M
−$30.0M
Tax rate (%)
0.0%
0.0%
0.0%
0.0%
0.0%
Net Profit
−$18.0M
−$20.0M
−$27.0M
−$29.0M
−$30.0M
EPS
−$0.42
−$0.48
−$0.64
−$0.65
$0.00
Balance Sheet — 1 Years (USD millions)
Metric
2025
Total Assets
$149.0M
Current Assets
$144.0M
Cash
$52.0M
Inventory
$0
Receivables
$1.0M
Fixed Assets
$2.0M
Capital Work in Progress
$0
Investments
$86.0M
Other Assets
$0
Total Liabilities
$388.0M
Current Liabilities
$14.0M
Borrowings
$2.0M
Other Liabilities
$386.0M
Equity
$0
Reserves
−$239.0M
Cash Flow Statement — 1 Years (USD millions)
Metric
2025
Operating Cash Flow
−$81.0M
Investing Cash Flow
$10.0M
Financing Cash Flow
−$1.0M
Net Cash Flow
$28.0M
Free Cash Flow
−$82.0M
Valuation & Return Ratios
Metric
Value
PEG Ratio
-0.25
EV / EBITDA
-19.95
FCF Yield
-4.03%
Quick Ratio
33.10
Interest Coverage
-160.00
Return 1Y
—
Return 3Y
—
Return 5Y
—
Avalyn Pharma Inc. (AVLN) financials — frequently asked questions
What is Avalyn Pharma Inc.'s annual revenue?
Avalyn Pharma Inc. (AVLN) reported annual revenue of $0 in its most recent fiscal year.
What is Avalyn Pharma Inc.'s net profit?
Avalyn Pharma Inc. (AVLN) reported a net loss of $85.0M in its most recent fiscal year.
What is AVLN EV/EBITDA?
Avalyn Pharma Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -19.95. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.
Revenue and earnings of other Biotechnology stocks